Evidence map›Paper›PMID 42841346›Full record

ArticleMolecular oncology2026

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer.

Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz-Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shikha RaniTranslational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, Australia.
Dominic GuanzonTranslational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, Australia.
Andrew LaiTranslational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, Australia.
Katherin Scholz-RomeroTranslational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, Australia.
Sarah ReedMass Spectrometry Facility, Frazer Institute, University of Queensland, Brisbane, Australia.
Edita RitmejeryteMass Spectrometry Facility, Frazer Institute, University of Queensland, Brisbane, Australia.
Rohan LourieMater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, Australia.
Naven ChettyMater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, Australia.
Kaltin FergusonMater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, Australia.
Carlos SalomonTranslational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, Royal Brisbane and Women's Hospital, The University of Queensland, Herston, Australia.ORCID https://orcid.org/0000-0003-4474-0046

Funding

Medical Research Future Fund MRF1199984National Health and Medical Research Council 1195451Ovarian Cancer Research Foundation 2018001167The Donald & Joan Wilson Foundation Ltd 2020000323
6 · The paper itself

Abstract

Ovarian cancer is the most lethal gynecological malignancy, due to late-stage diagnosis, tumor heterogeneity, and lack of biomarkers for early detection. Extracellular vesicles (EVs) in plasma and ascites offer a minimally invasive source of tumor-derived information, yet their lipid composition and relationship to tumor heterogeneity remain poorly defined. We performed lipidomic profiling of EVs from plasma and ascites of high-grade serous ovarian cancer patients and from ovarian cancer and control cell lines to identify signatures of tumor progression and microenvironmental interactions. A lipid panel enriched in ovarian cancer EVs was evaluated in EVs and plasma across two independent cohorts (n = 146). Combined with CA125, this panel improved detection, particularly against benign adnexal masses, achieving an AUROC of 0.99 in the verification cohort in both formats. Ovarian cancer EVs preferentially accumulated triglycerides, including ether-linked species, whereas parental cells were enriched in phospholipids and ceramides. EV lipid signatures reflected tumor-associated metabolic reprogramming and captured tumor heterogeneity across cell models. These findings show that EV lipidomics from accessible biofluids offers a non-invasive window into ovarian cancer metabolism and candidate biomarkers for patient stratification and monitoring.

Indexed as

biofluidsextracellular vesicleslipidomicsliquid biopsyovarian cancer cells

Identifiers

PMID42841346
PMCPMC13643885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.